Lipid overload - a culprit for hypertrophic cardiomyopathy?

References

[1] Maron BJ.Hypertrophic cardiomyopathy.The Lancet2013;381:242-55

[2] Ho CY,Ashley EA.Genotype and ifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe).Circulation2018;138:1387-98 PMCID:PMC6170149

[3] Yotti R,Seidman JG.Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies.Annu Rev Genomics Hum Genet2019;20:129-53

[4] Davis J,Correll RN.A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy.Cell2016;165:1147-59 PMCID:PMC4874838

[5] Kehat I,Tiburcy M.Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth.Circ Res2011;108:176-83 PMCID:PMC3032171

[6] Pua CJ,Chin CWL.Genetic studies of hypertrophic cardiomyopathy in singaporeans identify variants in TNNI3 and TNNT2 That are common in Chinese patients.Circ Genom Precis Med2020;13:424-34 PMCID:PMC7676617

[7] Mogensen J,Lambrecht S.A Systematic review of phenotypic features associated with cardiac troponin I mutations in hereditary cardiomyopathies.Can J Cardiol2015;31:1377-85

[8] Mogensen J,Kubo T.Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy.J Am Coll Cardiol2004;44:2315-25

[9] Hu J, Xiang Li J, Hong K, Xin Hu J, Brugada P, Shu Cheng X. Hypertrophic cardiomyopathy and planned in vitro fertilization. Genetic testing and clinical evaluation.Herz2012;37:447-52

[10] Guo L,Chen C.The TNNI3 p.R186Q mutation is responsible for hypertrophic cardiomyopathy via promoting FASN-stimulated abnormal fatty acid metabolism.J Cardiovasc Aging2023;3:6

[11] van der Velden J,Varricchi G.Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.Cardiovasc Res2018;114:1273-80 PMCID:PMC6054261

[12] Previs MJ,Morley MP.Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy.Circ Heart Fail2022;15:e009521 PMCID:PMC9708114

[13] Ranjbarvaziri S,Ellenberger M.Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy.Circulation2021;144:1714-31 PMCID:PMC8608736

[14] Wang Y,Solis RS.Generation and functional characterization of knock-in mice harboring the cardiac troponin I-R21C mutation associated with hypertrophic cardiomyopathy.J Biol Chem2012;287:2156-67 PMCID:PMC3265894

[15] Spertus JA,Elliott P.Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet2021;397:2467-75